# Creatine monohydrate

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Compound
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/creatine-monohydrate-muscle-brain-and-bone-evidence.html

> Creatine monohydrate refills the phosphocreatine energy buffer in muscle and brain. The evidence is strongest for muscle, more than a thousand trials supporting lean-mass and strength gains, including in older adults, while newer RCTs and meta-analyses support cognition under metabolic stress and depression augmentation, and 2-year data shows bone-geometry, not bone-density, benefits. Safety in healthy people is well supported over multi-year use; effects in rested young adults are minimal.

> **Form:** Creatine monohydrate (CrM) — the only form with a deep evidence base; all "advanced" forms (HCl, buffered, liquid) lack superiority data. **Status:** The most-studied ergogenic supplement in existence (>1,000 trials), now with rapidly accruing evidence in cognition, depression, menopause, and bone health (2024–2026 wave).

* * *

## Overview

In supplementation studies, 3–5 g/day of creatine monohydrate raised muscle phosphocreatine (PCr) 20–40%. Long dismissed as a "bodybuilder supplement," creatine is now one of the few compounds with human RCT evidence spanning muscle performance, brain bioenergetics, mood disorders, and postmenopausal bone geometry — with a 2025 ISSN position stand for older adults and clinical populations (Candow et al., 2025).

**Evidence Level:** Very strong for muscle/strength; moderate and growing for cognition under stress, depression augmentation, and bone geometry; mixed for resting cognition in healthy young adults.

* * *

## Mechanism of Action

### 1\. The Phosphocreatine / Creatine Kinase System

PCr acts as a spatial and temporal energy buffer: \- **Temporal buffering:** The creatine kinase reaction (PCr + ADP + H⁺ ↔ Cr + ATP) regenerates ATP in milliseconds during high-intensity demand \- **Proton buffering:** Consumes H⁺, attenuating acidosis during anaerobic effort \- **Spatial energy shuttling:** The PCr/Cr circuit moves high-energy phosphates from mitochondria (where ATP is made) to sites of use (myofibrils, ion pumps) — functionally analogous to a cellular charge/discharge cycle

### 2\. Brain Bioenergetics

The brain consumes ~20% of resting energy. Creatine kinase isoenzymes in neurons and astrocytes buffer ATP there too, and the brain's creatine pool is smaller and slower to load than muscle (blood–brain barrier limitation; weeks-to-months at low doses). This is why **cognitive effects reliably appear under metabolic stress** (sleep deprivation, hypoxia, aging, depression) but rarely in rested, healthy, well-slept young adults — the buffer isn't rate-limiting at baseline.

### 3\. Other Mechanisms

  * **Myonuclei retention / satellite cell activity** in older adults (anti-sarcopenic)
  * **Anti-inflammatory and antioxidant effects** (indirect, via improved Ca²⁺ handling)
  * **Brain pH and NAA ratio changes** visible on ³¹P/¹H-MRS spectroscopy — the cleanest in-vivo biomarker of target engagement



* * *

## Evidence Taxonomy

### A. Muscle Strength, Power, Lean Mass — HUMAN, STRONG

The base layer. Meta-analyses of RCTs consistently show CrM + resistance training increases lean mass (~1–1.5 kg over training alone) and 1RM strength (~8% additive). Effects hold in older adults (60–80+), where the myonuclei-retention mechanism matters most. See the 2025 ISSN position stand (Candow et al., _J Int Soc Sports Nutr_ 22(sup1):2534130) covering older adults and clinical populations.

### B. Cognition Under Metabolic Stress — HUMAN, MODERATE–STRONG

  * **Sleep deprivation:** Gordji-Nejad et al. 2024 (_Sci Rep_ 14:4937, open access) — randomized, double-blind, crossover; single **high dose 0.35 g/kg** (~25 g) during 21 h partial sleep deprivation. ³¹P/¹H-MRS showed increased brain PCr/tCr and reduced ATP/Pi; significant improvements in word memory, processing speed, logic, and numeric tasks vs placebo, plus reduced subjective fatigue. Acute brain bioavailability demonstrated — but note the dose is ~5× maintenance.
  * **Systematic review, cognition:** Xu et al. 2024 (_Front Nutr_ , PMID [39070254](https://pubmed.ncbi.nlm.nih.gov/39070254/); corrigendum PMID [40034739](https://pubmed.ncbi.nlm.nih.gov/40034739/)) — improved short-term memory and intelligence/reasoning; other domains inconsistent.
  * **Pattern:** effects concentrate in sleep loss, hypoxia, aging, and mental fatigue; minimal effect in rested healthy adults. Consistent with the buffer-not-limiting model above.



### C. Depression and Mental Disorders — HUMAN, GROWING

  * **RCT, augmentation:** Sherpa et al. 2025 (_Eur Neuropsychopharmacol_ 90:28–35) — 8-week double-blind pilot: CrM added to cognitive-behavioral therapy in depression showed better safety/feasibility and symptom signal vs placebo + CBT.
  * **Meta-analysis:** Eckert et al. 2025 (_Br J Nutr_ , published Nov 2025) — systematic review of RCTs on creatine for depressive symptoms.
  * **Systematic review of mental disorders RCTs** ([PMC12823350](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12823350/), search through Sep 2025) — pooled evidence across depression, anxiety, schizophrenia; generally small-to-moderate effects, strongest as adjunct in depression (esp. in women, aligned with Lyoo et al. 2012 SSRI augmentation precedent).
  * **Editorial framing:** Fabiano & Stubbs 2025 (_Eur Neuropsychopharmacol_ 95:1) — "muscle and the mind" hypothesis: creatine + exercise for depression.



### D. Postmenopausal Women — Muscle and Bone — HUMAN, ACTIVE CONTROVERSY (2026)

This is the current research frontier: \- **Meta-analysis 2026:** Naddafha et al. 2026 (_J Int Soc Sports Nutr_ , PMID [42141930](https://pubmed.ncbi.nlm.nih.gov/42141930/) / [PMC13182165](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13182165/)) — RCTs in postmenopausal women: benefits for lean mass and strength; **bone mineral density effects not significant** , but bone _geometry_ signals. \- **2-year RCT:** Chilibeck et al. 2023 (_Med Sci Sports Exerc_ 55(10):1750–1760) — n=237 postmenopausal women, creatine ~0.1–0.14 g/kg/day + exercise for 2 years: **no BMD change** at femoral neck/hip/spine, but improved **section modulus and buckling ratio** (bone strength geometry) at femur. \- **Earlier signal:** Candow et al. 2021 (_Osteoporos Int_ , PMID [33052328](https://pubmed.ncbi.nlm.nih.gov/33052328/)) — smaller trials suggesting attenuated bone loss; and a 52-week 1 g/day trial (Lobo et al. 2015) showing femoral bone content ~+1.8% vs +0.4% placebo. \- **Counterpoint:** Osteoporos Int 2025 commentary (10.1007/s00198-025-07713-9) — "insufficient evidence to recommend creatine for osteoporosis." \- **Bottom line:** BMD is not meaningfully improved; bone _structural geometry_ and muscle-related fall-fracture risk factors may be. Doses in positive trials (0.1–0.14 g/kg/day ≈ 7–10 g/day) exceed the standard 3–5 g.

### E. Traumatic Brain Injury / Neuroprotection — HUMAN PRELIMINARY + ANIMAL

Pediatric TBI RCTs (Sakellaris et al.) showed improved outcomes; adult data lacking. Animal data robust across TBI, spinal cord injury, Huntington's models. Not clinical practice yet.

### F. Vegetarians / Older Adults — Special Populations

Vegetarians and vegans start with lower baseline muscle and brain creatine pools and show the largest response deltas. Older adults need the muscle anti-sarcopenia angle more than the sports angle — see [Exercise Science and Longevity](exercise-science-and-longevity.html).

* * *

## Uses

  * **Timing:** Post-workout slightly superior in some trials; consistency matters more than timing.
  * **No cycling needed; no credible evidence of receptor downregulation** — creatine is a substrate, not a signal.
  * **Response variability:** ~20–30% "non-responders" for muscle performance (high baseline pools); vegans respond most.
  * **Form:** Monohydrate only. Creapure® vs generic: purity differences minor; third-party testing (NSF/Informed Sport) matters in tested sport.



* * *

## Safety

  * **Renal:** No evidence of kidney harm in healthy individuals across trials up to 5 years (Kreider et al. 2025, _J Int Soc Sports Nutr_ — safety analysis of trials + adverse-event reports). Contraindication caution remains for pre-existing renal disease.
  * **Postmenopausal women:** 2-year trials show adverse events comparable to placebo (Chilibeck 2023).
  * **Water retention:** Early intracellular (+1–2 kg); not fat mass.
  * **Hair loss:** Single small 2009 rugby study (rugby confound); never replicated — treat as myth pending data.
  * **Long-term:** 5+ year pediatric TBI and adult neurology trials without signal emergence.



* * *

## Open Questions / Research Gaps

  1. **BMD vs bone geometry** — 2-year trials dissociate density from strength geometry; fracture-outcome data absent entirely.
  2. **Brain loading kinetics** — how many weeks of what dose maximally loads the human brain (MRS studies ongoing)?
  3. **Depression augmentation** — Sherpa 2025 was a pilot; adequately powered Phase-2-style trials still missing.
  4. **Sex differences** — women underrepresented historically; menstrual-phase interactions barely studied (one study: CrM increases sleep duration post-resistance-training in naturally menstruating women).



* * *

## Sources

1. Xu C, et al. (2024). "The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis." Front Nutr . PMID 39070254 (corrigendum: PMID 40034739 ). (PubMed 39070254, PubMed 40034739)
2. PMC12823350 (PMC12823350)
3. Naddafha S, et al. (2026). "Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis." J Int Soc Sports Nutr . PMID 42141930 , PMC13182165 . (PubMed 42141930, PMC13182165)
4. Candow DG, et al. (2021). "Creatine supplementation and changes in bone mineral density in women aged 50–70 years." Osteoporos Int 32:989–998. PMID 33052328 . (PubMed 33052328)